Emergency Endovascular Aneurysm Repair for Ruptured Abdominal Aortic Aneurysm: The Way Forward?
| Autor: | Rachel Bell, Rachel E. Clough, J. F. Reidy, Tarun Sabharwal, Tom Carrell, Stephen Black, Oliver Lyons, Peter N Taylor, Matthew Waltham |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Patient Transfer Reoperation medicine.medical_specialty Time Factors Critical Care Aortic Rupture medicine.medical_treatment Hemodynamics Aortography Endovascular aneurysm repair Blood Vessel Prosthesis Implantation Aortic aneurysm Aneurysm medicine.artery medicine Humans Radiology Nuclear Medicine and imaging Hospital Mortality Aged Retrospective Studies Aged 80 and over Aorta business.industry Retrospective cohort study General Medicine Length of Stay Middle Aged medicine.disease Abdominal aortic aneurysm Surgery Treatment Outcome Female Radiology Cardiology and Cardiovascular Medicine business Tomography Spiral Computed Aortic Aneurysm Abdominal Program Evaluation Abdominal surgery |
| Zdroj: | Vascular. 18:130-135 |
| ISSN: | 1708-539X 1708-5381 |
| DOI: | 10.2310/6670.2010.00033 |
| Popis: | We present the early results of a policy of treating all anatomically suitable ruptured abdominal aortic aneurysms (rAAAs) by emergency endovascular aneurysm repair (eEVAR), regardless of hemodynamic instability. Data were retrospectively collected from prospectively maintained databases identifying patients with rAAA from 2006 to 2007. Forty-seven patients with true rAAA were identified (87% men; median age 76 years [range 63–97 years]), of whom 18 (38%) were treated with eEVAR, 19 (40%) received open aneurysm repair (OAR), and 10 (21%) were managed nonoperatively. Fifteen of 18 (83%) eEVAR patients received an aortouni-iliac device + femorofemoral crossover, 2 patients (11%) had bifurcated devices, and 1 patient (6%) had a new iliac limb. Thirty-day mortality was 11% (2 of 18) for eEVAR and 32% (6 of 19) for OAR ( p = not significant). At the 6-month follow-up, mortality was 22% (4 of 18) for eEVAR and 37% (7 of 19) for OAR ( p = not significant). A clinically significant early survival advantage is suggested for eEVAR in patients presenting with rAAA. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|